Minimal Residual Disease clinical trials

Explore recruiting minimal residual disease clinical trials.

Recruiting minimal residual disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Minimal Residual Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

Italy, Germany, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma CARTITUDE-2

Spain, Netherlands, Germany, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM

Belgium, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Multi-Center Phase III Trial comparing two conditioning regimens (CloFluBu and BuCyMel) in children with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation.

Finland, Sweden, Denmark, Netherlands, Norway, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Netherlands, Denmark, Belgium, France, Italy, Spain +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS or oligoblastic AML

Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Minimal Residual Disease trials by city

Minimal Residual Disease in Toronto Minimal Residual Disease in Vancouver Minimal Residual Disease in Montreal Minimal Residual Disease in Calgary Minimal Residual Disease in Edmonton Minimal Residual Disease in Ottawa Minimal Residual Disease in Winnipeg Minimal Residual Disease in Quebec City Minimal Residual Disease in Hamilton Minimal Residual Disease in Kitchener Minimal Residual Disease in London Minimal Residual Disease in Halifax Minimal Residual Disease in New York Minimal Residual Disease in Los Angeles Minimal Residual Disease in Chicago Minimal Residual Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease